Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs

Mayo Clinic Proceedings

Volumn 72, Issue 9, 1997, Pages 835-847

  Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; CAPTOPRIL; CHLORPROMAZINE; CLOMIPRAMINE; CODEINE; DESIPRAMINE; DIHYDROCODEINE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HYDROCODONE; IMIPRAMINE; LABETALOL; MAPROTILINE; METOPROLOL; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OXYCODONE; PAROXETINE; PERPHENAZINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; UNINDEXED DRUG; VENLAFAXINE;

DEPRESSION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; REVIEW;

EID: 0030867948     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.9.835     Document Type: Review

References (105)

1. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081
2. Chutka DS, Evans JM, Fleming KC, Mikkelson KG. Drug prescribing for elderly patients. Mayo Clin Proc 1995;70:685-693
3. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713
4. Holstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol 1993;72:50B-52B
5. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-160
6. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:l-42
7. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-1194
8. Bork RW, Muto T, Beaune PH, Srivastava PK, Lloyd RS, Guengerich FP. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. JBiolChem 1989;264:910-919
9. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993;57:129-160
10. Kroemer HK, Eichelbaum M. It's the genes, stupid: molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-2298
11. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993;3:275-280
12. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-156
13. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409
14. Sellers EM, Ball SE, Cheung S W, Inaba T, Otton S V. Inhibition by venlafaxine (VF) and other 5-HT uptake inhibitors of the polymorphic enzyme CYP2D6 [abstract]. In: Program and Abstracts of the 32nd Annual Meeting of the American College of Neuropsychopharmacology; 1993 Dec 13-17; Honolulu (HI). 1993. p 163
15. Coutts RT. Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J Psychiatry Neurosci 1994; 19:30-44
16. Sjoqvist F, Alexanderson B, Asberg M, Bertilsson L, Borga O, Hamberger B, et al. Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol 1971;29(Suppl 3):255-280
17. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-408
18. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76
19. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996;60:138-144
20. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285299
21. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-159
22. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994:56:471-476
23. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988;43:412419
24. Nielsen KK, Flinois JP, Beaune P, Br0sen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277:1659-1664
25. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996;37:253-257
26. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997;61:8-14
27. Madsen H, Nielsen KK, Br0sen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms-a population study. Br J Clin Pharmacol 1995;39:433439
28. Otton SV, Inaba T. Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984;34:73-80
29. Eap CB, Laurian S, Souche A, Koeb L, Reymond P, Buclin T, et al. Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers: a pilot study on two subjects. Neuropsychobiology 1992;25:214-220
30. Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in Ndemethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993;3:291-301
31. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly byCYP!A2. Br J Clin Pharmacol 1995;39:421-431
32. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, ShaderRI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31
33. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-1283
34. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131
35. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans [editorial] [published erratum appears in J Clin Psychopharmacol 1996;16:344]. J Clin Psychopharmacol 1996;16:267272
36. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 1994;4:359-362
37. Verhoeven CHJ, Vos RME, Bogaards JJP. Characterization and inhibition of human cytochrome P-450 enzymes involved in the in vitro metabolism of mirtazapine [abstract]. Eur Neuropsychopharmacol 1996;6(Suppl 4):63
38. Ball S, Ahern D, Kao J, Scatina J. Venlafaxine (VF): effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMI) 2hydroxylation; comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4 and CYP2C9 [abstract]. Clin Pharmacol Ther 1996;59:170
39. von Moltke LL, Duan SX, Greenblatt DJ, Fogelman SM, Schmider J. Harmatz JS, et al. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3 A isoforms. Biol Psychiatry 1997:41:377-380
40. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-791
41. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-355
42. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed l'-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995;275:1131-1135
43. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-597
44. Pirmohamed M, Williams D, Madden S, Templeton E. Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995:272:984-990
45. Bertilsson L, Carrillo JA, Dahl ML. Llerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471473
46. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-832
47. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74
48. Nebert DW, Petersen DD, Puga A. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991; 1:68-78
49. Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. Br J Clin Pharmacol 1983; 16:157-166
50. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-127
51. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5:259-274
52. Br0sen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214
53. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 1996; 128:398-407
54. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(Suppl):84S-99S
55. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15:243-246
56. Jeppesen U, Loft S, Poulsen HE, Br0sen K. A fluvoxaminecaffeine interaction study. Pharmacogenetics 1996;6:213-222
57. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Br0sen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78
58. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153:820-822
59. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11 -year-old boy. Drug Saf 1991;6:460462
60. van den Brekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994; 151:1289-1290
61. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both Smephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994;38:131-137
62. Woolfrey S, Gammack NS, Dewar MS, Brown PJ. Fluoxetinewarfarin interaction [letter]. BMJ 1993;307:241
63. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991 ;6(Suppl 2): 11 -21
64. Wilner KD, Lazar JD, Apseloff G, Gerber N, Yurkewick L. The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers [abstract]. Biol Psychiatry 1991;29(Suppl):354S-355S
65. Physicians' Desk Reference. 51st ed. Montvale (NJ): Medical Economics; 1997. pp 2051-2053
66. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants [letter]. Am J Psychiatry 1988;145:1478
67. Crewe HK, Leonard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
68. Skjelbo E, Br0sen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-261
69. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996;41:339-343
70. von Bahr C, Spina E, Birgersson C, Ericsson O, Goransson M, Henthorn T, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985;34:2501-2505
71. Amchin JD, Ereshefsky L, Zarycranski WM. Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan, a CYP2D6 marker [abstract]. In: Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York. Washington (DC): American Psychiatric Association Press; 1996. p 165
72. Lam YWF, Ereshefsky L, Riesenman C, Simpson J. In vivo comparison of CYP2D6 inhibition among SSRIs: implications for drug interactions [abstract]. In: Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York. Washington (DC): American Psychiatric Association Press; 1996. p 176
73. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-379
74. Greene DS, Dockens RC, Salazar DE, Barbhaiya RH. Coadministration of nefazodone (NEF) and benzodiazepines I: pharmacokinetic assessment [abstract]. Clin Pharmacol Ther 1994;55:141
75. De Vane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. AmJMed 1994;97(Suppl 6A):S13-S23
76. Amchin J, Zarycranski W. Effect of venlafaxine on the pharmacokinetics of alprazolam [abstract]. Psychopharmacol Bull 1996; 32:411
77. WiklanderB, DanjouP, RolanP, TaminSK,ToonS. Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine [abstract]. Eur Neuropsychopharmacol 1995;5:310-311
78. Amchin JD, Zarycranski WM, Taylor K. Venlafaxine's lack of CYP3A4 inhibition is further confirmed by an in vivo study with terfenadine [abstract]. In: Program and Abstracts of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9-13; San Juan (PR). 1996. p 110
79. Everitt DE, Martin DE, Zussman BD, Benincosa LJ, Etheredge R, Jorkasky DK. No effect of paroxetine on the cardiac safety and pharmacokinetics of terfenadine [abstract]. In: Program and Abstracts of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9-13; San Juan (PR). 1996. p 172
80. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines. III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995; 15:399-408
81. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines. II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-326
82. Physicians' Desk Reference. 51st ed. Montvale (NJ): Medical Economics; 1997. pp 776-779
83. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-131
84. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-956
85. Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:2533
86. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248
87. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486
88. Shader Rl, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism [editorial]. J Clin Psychopharmacol 1994; 14:375-376
89. Seifritz E, Holsboer-Trachsler E, Hemmeter U, Eap CB, Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol 1994:4:15-20
90. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993:110:302-308
91. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-374
92. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994:46:35-39
93. Physicians' Desk Reference. 51st ed. Montvale (NJ): Medical Economics; 1997. pp 2723-2727
94. Salazar DE, Dockens RC, Milbrath RL, Raymond RH, Fulmor IE, Chaikin PC, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-738
95. Alderman J, Greenblatt DJ. Allison J, Preskorn S, Harrison W, Chung M. Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline [abstract]. In: Proceedings of the 147th Annual Meeting of the American Psychiatric Assocation; 1994 May 21-26; Philadelphia. Washington (DC): American Psychiatric Association Press; 1994
96. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029
97. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14:90-98
98. Barros J, Asnis G. An interaction of sertraline and desipramine [letter]. Am J Psychiatry 1993;150:1751
99. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants [letter]. Am J Psychiatry 1993:150:1125-1126
100. Zussman BD, Davie CC, Fowles SE, Kumar R, Lang U. Wargenau M, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo [abstract]. In: Program and Abstracts of the 33rd Annual Meeting of the American College of Neuropsychopharmacology; 1994 Dec 12-16; San Juan (PR). 1994. p 107
101. Joblin M. Possible interaction of sertraline with carbamazepine [letter]. N Z Med J 1994;107:43
102. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57(Suppl l):20-23
103. Apseloff G, Wilner KD. Gerber N. Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32(Suppl l):37-42
104. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997;32(Suppl l):31-36
105. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM. Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995:35:410-419